



241 | 11 | 0
Views | CrossRef citations to date | Altmetric

Original Article

Projected economic impact of clinical findings of generic entry of topiramate on G4 European countries

Pierre Emmanuel Paradis, Dominick Latrémouille-Viau, Yuliya Moore, Natalia Mishagina, Marie-Hélène Lafeuille, Patrick Lefebvre, ... [show all](#)

Pages 1793-1805 | Accepted 15 May 2009, Published online: 05 Jun 2009

🗨 Cite this article 🔗 <https://doi.org/10.1185/03007990903044374>

Sample our
Bioscience
Journals
[>> Sign in here](#) to start your access
to the latest two volumes for 14 days

We Care About Your Privacy

We and our 907 partners store and access personal data, like browsing data or unique identifiers, on your device. Selecting "I Accept" enables tracking technologies to support the purposes shown under "we and our partners process data to provide," whereas selecting "Reject All" or withdrawing your consent will disable them. If trackers are disabled, some content and ads you see may not be as relevant to you. You can resurface this menu to change your choices or withdraw consent at any time by clicking the ["privacy preferences"] link on the bottom of the webpage [or the floating icon on the bottom-left of the webpage, if applicable]. Your choices will have effect within our Website. For more details, refer to our Privacy Policy. [Here](#)

We and our partners process data to provide:

...

I Accept

Reject All

Show Purpose

versus generic use of topiramate. Canadian healthcare utilization and costs (2007 CAN\$/person-year) were compared between periods using multivariate models. Annualized per-patient costs (2007€ or 2007£/person-year) were converted using Canadian utilization rates, European prices and service-use ratios. Non-parametric bootstrap served to assess statistical significance of cost differences. Topiramate market was forecasted following generic entry (09/2009–09/2010) using autoregressive models based on the European experience. The economic impact of generic topiramate entry was estimated for each country.

Results: A total of 1164 patients (mean age: 39.8 years, 61.7% female) were observed for 2.6 years on average. After covariates adjustment, generic-use periods were associated with increased pharmacy dispensings (other AEDs: +0.95/person-year, non-AEDs: +12.28/person-year, $p < 0.001$), hospitalizations (+ 0.08/person-year, $p = 0.015$), and lengths of hospital stays (+0.51 days/person-year, $p < 0.001$). Adjusted costs, excluding topiramate, were CAN\$1060/person-year higher during generic use ($p = 0.005$). Converted per-patient costs excluding topiramate were significantly higher for generic relative to brand periods in all European countries (adjusted cost differences per person-year: €706–815, $p < 0.001$ for all comparisons). System-wide costs would increase from 3.5 to 24.4% one year after generic entry.

Limitations: Study limitations include the absence of indirect costs, possible claim inaccuracies.

Conclusion: Generic entry of topiramate was associated with increased costs from the Canadian perspective.

Key words:

Antiepileptic



Transp

Declar

This ana

Pharmaceutica NV.

Declaration of financial/other relationships

M.G. has disclosed that she is an employee of Janssen-Cilag EMEA. All other co-authors disclosed that they are employees of Analysis Group, Inc., which has received research grants to conduct this study from Janssen-Cilag EMEA.

All peer reviewers receive honoraria from CMRO for their review work. Peer reviewer 1 disclosed that he/she has received grant support from GlaxoSmithKline. Peer reviewer 2 disclosed that he/she has no relevant financial relationships.

Acknowledgment

Janssen-Cilag EMEA participated in the design, review, and approval of the manuscript. The authors disclosed no further assistance in preparation of this manuscript.

Notes

† Topamax is a registered trade name of Ortho-McNeil Neurologics, Inc., Titusville, NJ, USA

*Topamax is a registered trade name of Ortho-McNeil Neurologics, Inc., Titusville, NJ, USA

×

Relat

T

Source

Estim

Struc

Source

Off-p

Source

Movin

Source: Unknown Repository



es with

Economic impact of generic substitution of lamotrigine: projected costs in the US using findings in a Canadian setting

Source: Current Medical Research and Opinion

Are there potential problems with generic substitution of antiepileptic drugs?

Source: Seizure

Compulsory Generic Switching of Antiepileptic Drugs: High Switchback Rates to Branded Compounds Compared with Other Drug Classes

Source: Epilepsia

Therapeutic equivalency of generic antiepileptic drugs: results of a survey

Source: Epilepsy & Behavior

Clinical consequences of generic substitution of lamotrigine for patients with epilepsy

Source: Neurology

Do Drugs Reduce Utilisation of Other Healthcare Resources?

Source: Pharmacoeconomics

Bias and causal associations in observational research

Source: The Lancet

Outbreak of Anticonvulsant Intoxication in an Australian City

Source: BMJ

Patient and physician reactions to generic antiepileptic substitution in the treatment of epilepsy

Source: Epilepsy & Behavior

Cost of refractory epilepsy in adults in the USA

Source:

Who's

Source:

Linkin



Share



Related

Information for

- Authors
- R&D professionals
- Editors
- Librarians
- Societies

Opportunities

- Reprints and e-prints
- Advertising solutions
- Accelerated publication
- Corporate access solutions

Open access

- Overview
- Open journals
- Open Select
- Dove Medical Press
- F1000Research

Help and information

- Help and contact
- Newsroom
- All journals
- Books

Keep up to date

Register to receive personalised research and resources by email

 Sign me up



Copyright © 2024

Accessibility

Registered in England
5 Howick Place

Wiley or Francis Group
a John Wiley & Sons business

